SIGA的抗病毒药物Tepoxx获得日本对治疗天花及相关病毒的首次批准。 SIGA's antiviral drug Tepoxx gains Japan's first approval for treating smallpox and related viruses.

SIGA技术的抗病毒药物Tepoxx,经日本批准,治疗天花、猴子天花及相关病毒,标志着日本首次批准这种治疗。 SIGA Technologies' antiviral drug Tepoxx, approved in Japan, treats smallpox, monkeypox, and related viruses, marking Japan's first approval for such a treatment. 该药物已经获得美国和欧盟的批准,将由独家经销商日本生物技术制药公司供应给日本的库存。 The drug, already approved in the US and EU, will be supplied to Japan's stockpile by exclusive distributor Japan Biotechno Pharma. 根据临床试验数据核准,Tepoxx将VP37蛋白质作为抑制病毒扩散的目标。 Approved based on clinical trial data, Tepoxx targets the VP37 protein to inhibit viral spread.